The Motley Fool
01 Aug 2026, 17:08 UTC · 3h ago
Is Grail (GRAL) Stock a Buy, Sell, or Hold at Under $70?
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
The Motley Fool
01 Aug 2026, 17:08 UTC · 3h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
Grail's largest NHS England trial failed to meet its primary endpoint, complicating the path toward FDA approval. — Failure of a primary endpoint in a major trial creates significant regulatory hurdles for FDA approval and insurance coverage, which are critical for mass-market scaling.
-0.80Analysts project Grail's revenue to grow from $147 million in 2025 to $281 million by 2028. — Steady projected revenue growth indicates business viability and market adoption despite the lack of immediate profitability.
+0.40Grail is currently selling its Galleri test on a cash-only basis to independent customers, employers, and hospital pilots. — Direct-to-consumer and private sales provide a revenue floor and proof-of-concept while awaiting regulatory breakthroughs.
+0.20Which stocks this story touches
Continue reading
6 related stories
Top 2 movers · tap to explore
The stock has declined significantly from record highs after a major NHS trial failed to meet its primary endpoint.
The company is mentioned only as the former parent company of Grail with no news affecting its own operations.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
GlobeNewsWire
5h ago
